Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Ablynx, a Sanofi company180 enrolled

Overview

The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI). The secondary objective is to evaluate the clinical activity, pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different doses of inhaled ALX-0171.

This was a Phase 2b, randomized, double-blind, placebo-controlled, international, multicenter dose-ranging study in infants and toddlers hospitalized for RSV LRTI. The study evaluated 3 dose levels of ALX-0171 in a sequential part (safety Cohorts 1-3) followed by a parallel part (Cohort 4). An Independent Data Monitoring Committee (IDMC) was assigned to review study data and provide recommendations on proceeding to the next safety cohort and on which dose levels could be taken forward in the parallel part. Three dose levels of ALX-0171 were evaluated: * Dose 1: target dose of 3.0 mg/kg * Dose 2: target dose of 6.0 mg/kg * Dose 3: target dose of 9.0 mg/kg The study drug was administered by inhalation once daily for 3 consecutive days along with standard of care treatment, which was determined by the Investigator (or his/her designee) according to institutional practice.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

180

Conditions

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Interventions

ALX-0171 3.0 mg/kgBIOLOGICAL

ALX-0171 6.0 mg/kgBIOLOGICAL

ALX-0171 9.0 mg/kgBIOLOGICAL

PlaceboOTHER

Eligibility

Sex: ALLMin age: 28 DaysMax age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female infant or young child aged 28 days to \< 2 years with gestational age ≥ 33 weeks at screening. 2. Subject weighed between ≥ 3.0 kg and \< 15.0 kg at screening. 3. Subject is otherwise healthy but was hospitalized for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnea, wheezing, cough, crackles, use of accessory muscles and/or nasal flaring. 4. Subject had a positive RSV diagnostic test at screening. 5. Subject was expected to have to stay in the hospital for at least 24 hours (according to the Investigator's judgment at screening). 6. Symptoms were likely related to RSV infection (i.e., the symptoms present needed to be probably linked to the current RSV infection according to Investigator's judgment) had appeared within 4 days of screening and were not yet improving at screening and randomization. 7. Subject fulfilled at least 2 of the following RSV disease severity criteria at screening and randomization: * Inadequate oral feeding that required feeding support (i.e., nasogastric tube or intravenous \[i.v.\] line) * Inadequate oxygen saturation defined as: * Oxygen saturation (peripheral capillary oxygen saturation \[SpO2\]) ≤ 92% on room air or * Requiring oxygen supplementation to maintain oxygen saturation \> 90% with documented pre-supplementation value ≤ 92% * Signs of respiratory distress defined as: * Respiratory rate ≥ 50 per minute in infants up to 12 months of age, and ≥ 40 per minute in children above 12 months and/or * Moderate or marked respiratory muscle retractions 8. Normal psychomotor development. Exclusion Criteria: 1. Subject was known to have significant comorbidities including: * Genetic disorders (e.g., trisomy 21, cystic fibrosis), * Hemodynamically significant congenital heart disease (e.g., needing corrective therapy or inotropic support), * Bronchopulmonary dysplasia, * Any hereditary or acquired metabolic (bone) diseases, * Hematologic or other malignancy. 2. Subject was known to be human immunodeficiency virus (HIV)-positive. If the subject was \< 6 months of age, a known HIV-positivity of the mother was also exclusionary. 3. Subject was known to be immunocompromised. 4. Subject had or was suspected to have an active, clinically relevant concurrent infection (e.g., bacterial pneumonia, urinary tract infection). Concurrent acute otitis media was not exclusionary. 5. Subject had significant oral and/or maxillofacial malformations that would prevent proper positioning of the face mask. 6. Subject received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to screening. 7. During the admission, the subject was initially hospitalized in an intensive care unit (ICU) setting and/or had received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure). 8. Subject was critically ill and/or was expected to require invasive mechanical ventilation, non invasive respiratory support (i.e., continuous or bilevel positive airway pressure), or High Flow oxygen therapy (HFOT) at levels not enabling nebulization therapy according to the Investigator's judgment. High Flow oxygen, with a maximum flow of 2 L/kg/min, was permitted under the following conditions: * used as Standard of Care outside ICU setting * could be removed for study drug administration (Note: oxygen flow at 2 L/min could be provided)

Locations (74)

Outcomes

Primary Outcomes

Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis)

The primary endpoint for this trial was the time needed for the viral load to drop below the quantification limit (time-to-BQL) of the plaque assay in nasal mid-turbinate swab specimens. Time-to-BQL was defined as the time from the first study drug administration to the first occurrence of a value below the quantification limit (BQL), provided the next measured value was also below the limit of quantification. The time to BQL for subjects with missing data and/or who did not reach BQL during the trial were censored at the last non-missing viral load assessment. The primary endpoint was analysed using logrank test to compare time-to-BQL between each of the ALX-0171 treatment groups and the combined placebo group. The tests were performed in a sequential way to preserve the family-wise error rate at 0.05. The comparisons were performed in the following order: ALX-0171 9 mg/kg vs Placebo, followed by ALX-0171 6mg/kg vs Placebo, ALX-0171 3mg/kg vs Placebo.

Time frame: Overall Study Period (i.e., approximately 28 days)

Secondary Outcomes

Change From Baseline in Global Severity Score on Day 2 (5 Hours Post-dose)

A formal comparison for change from Baseline in GSS to Day 2, 5 hours post-dose was performed using a contrast analysis on a longitudinal mixed model with random factor subject and fixed effects baseline value, treatment group and timepoint, including the treatment-by-timepoint interaction term. All data up to and including Day 3 were used in the longitudinal mixed model. The Kenward-Roger approximation of degrees of freedom was used. The model was fitted using an unstructured variance-covariance matrix. The individual pair-wise comparisons were reported (comparison in least square \[LS\] means for 9.0 mg/kg versus placebo; 6.0mg/kg versus placebo; 3.0 mg/kg versus placebo). Evolution over time in Global Severity Score. The maximum total score is 20 (minimum:0 to manimum:20); higher score indicates more severe disease.

Time frame: from Baseline untill Day 2 (5 hours post-dose)

Time-to-Clinical Response

The time-to-clinical response was defined as the time between the first study drug administration and the time of achieving adequate oxygen saturation (defined as SpO2 \> 92% over a period of at least 4 hours) and adequate oral feeding (which is sufficient to maintain sufficient hydration, in the judgment of the Investigator).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.